We have more than 150 patents pending and 16 patents issued related to our ISA247 technology. These patents include compound claims, methods of manufacture, use claims and analytical methods. Our intellectual property position continues to be strengthened with the addition of this new patent. We will continue to pursue additional patentable claims for ISA247 where appropriate.

We are extremely pleased that data from our Phase III psoriasis trials of ISA247 will be presented to audiences that represent both dermatology and transplantation. We continue to be encouraged by the data generated in the SPIRIT extension trial and we believe ISA247 will continue to demonstrate continued efficacy with minimal toxicity.

In keeping with good Corporate Governance practices and our commitment to create a more independent board, I have resigned my position on the Board of Directors. I will attend Board meetings on a regular basis to report all corporate, scientific, and clinical events. Dr. Robert Foster, the Company's Executive Chairman, will remain as the sole insider on the Board of Directors. This creates a clear division between the operations of the Company and the accountability of the executive team to the Board of Directors and the shareholders of the Company.

We have taken the first step but there is at least a decade to go before this technology finds its way onto a spacecraft.

This is a technology called convection-enhanced delivery. And what it does is it pushes the chemotherapy to the areas where the tumor cells are hiding deep within the brain.

Whenever we go to a new technology, there are some cautious steps that should be taken. More studies have to be done in animals, as well as in humans, before the scientific community and the public in general have more faith in these newer approaches.